NASDAQ:VRDN

Viridian Therapeutics Competitors

$14.76
+0.42 (+2.93 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.24
Now: $14.76
$15.16
50-Day Range
$14.34
MA: $16.84
$18.65
52-Week Range
$7.08
Now: $14.76
$25.67
Volume13,507 shs
Average Volume53,321 shs
Market Capitalization$57.68 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Viridian Therapeutics (NASDAQ:VRDN) Vs. LBPH, IPA, GANX, ANVS, VINC, and EVAX

Should you be buying VRDN stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Viridian Therapeutics, including Longboard Pharmaceuticals (LBPH), ImmunoPrecise Antibodies (IPA), Gain Therapeutics (GANX), Annovis Bio (ANVS), Vincerx Pharma (VINC), and Evaxion Biotech A/S (EVAX).

Viridian Therapeutics (NASDAQ:VRDN) and Longboard Pharmaceuticals (NASDAQ:LBPH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Profitability

This table compares Viridian Therapeutics and Longboard Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viridian TherapeuticsN/AN/AN/A
Longboard PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and recommmendations for Viridian Therapeutics and Longboard Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viridian Therapeutics00203.00
Longboard Pharmaceuticals00503.00

Viridian Therapeutics presently has a consensus price target of $34.00, indicating a potential upside of 130.35%. Longboard Pharmaceuticals has a consensus price target of $32.75, indicating a potential upside of 181.60%. Given Longboard Pharmaceuticals' higher possible upside, analysts clearly believe Longboard Pharmaceuticals is more favorable than Viridian Therapeutics.

Earnings & Valuation

This table compares Viridian Therapeutics and Longboard Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridian TherapeuticsN/AN/AN/AN/AN/A
Longboard PharmaceuticalsN/AN/AN/AN/AN/A

Summary

Longboard Pharmaceuticals beats Viridian Therapeutics on 2 of the 2 factors compared between the two stocks.

ImmunoPrecise Antibodies (NASDAQ:IPA) and Viridian Therapeutics (NASDAQ:VRDN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Profitability

This table compares ImmunoPrecise Antibodies and Viridian Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunoPrecise AntibodiesN/AN/AN/A
Viridian TherapeuticsN/AN/AN/A

Valuation and Earnings

This table compares ImmunoPrecise Antibodies and Viridian Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoPrecise AntibodiesN/AN/AN/AN/AN/A
Viridian TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and price targets for ImmunoPrecise Antibodies and Viridian Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunoPrecise Antibodies01002.00
Viridian Therapeutics00203.00

Viridian Therapeutics has a consensus target price of $34.00, suggesting a potential upside of 130.35%. Given Viridian Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viridian Therapeutics is more favorable than ImmunoPrecise Antibodies.

Summary

Viridian Therapeutics beats ImmunoPrecise Antibodies on 3 of the 3 factors compared between the two stocks.

Gain Therapeutics (NASDAQ:GANX) and Viridian Therapeutics (NASDAQ:VRDN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Valuation and Earnings

This table compares Gain Therapeutics and Viridian Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gain TherapeuticsN/AN/AN/AN/AN/A
Viridian TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Gain Therapeutics and Viridian Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gain TherapeuticsN/AN/AN/A
Viridian TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings for Gain Therapeutics and Viridian Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gain Therapeutics00203.00
Viridian Therapeutics00203.00

Gain Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 106.90%. Viridian Therapeutics has a consensus target price of $34.00, indicating a potential upside of 130.35%. Given Viridian Therapeutics' higher possible upside, analysts plainly believe Viridian Therapeutics is more favorable than Gain Therapeutics.

Summary

Viridian Therapeutics beats Gain Therapeutics on 1 of the 1 factors compared between the two stocks.

Viridian Therapeutics (NASDAQ:VRDN) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Earnings and Valuation

This table compares Viridian Therapeutics and Annovis Bio's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridian TherapeuticsN/AN/AN/AN/AN/A
Annovis BioN/AN/AN/AN/AN/A

Profitability

This table compares Viridian Therapeutics and Annovis Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viridian TherapeuticsN/AN/AN/A
Annovis BioN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Viridian Therapeutics and Annovis Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viridian Therapeutics00203.00
Annovis Bio0000N/A

Viridian Therapeutics presently has a consensus price target of $34.00, suggesting a potential upside of 130.35%. Given Viridian Therapeutics' higher probable upside, analysts clearly believe Viridian Therapeutics is more favorable than Annovis Bio.

Summary

Viridian Therapeutics beats Annovis Bio on 2 of the 2 factors compared between the two stocks.

Viridian Therapeutics (NASDAQ:VRDN) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations.

Profitability

This table compares Viridian Therapeutics and Vincerx Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viridian TherapeuticsN/AN/AN/A
Vincerx PharmaN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and price targets for Viridian Therapeutics and Vincerx Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viridian Therapeutics00203.00
Vincerx Pharma00103.00

Viridian Therapeutics presently has a consensus target price of $34.00, suggesting a potential upside of 130.35%. Given Viridian Therapeutics' higher possible upside, equities research analysts clearly believe Viridian Therapeutics is more favorable than Vincerx Pharma.

Earnings and Valuation

This table compares Viridian Therapeutics and Vincerx Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridian TherapeuticsN/AN/AN/AN/AN/A
Vincerx PharmaN/AN/AN/AN/AN/A

Summary

Viridian Therapeutics beats Vincerx Pharma on 2 of the 2 factors compared between the two stocks.

Viridian Therapeutics (NASDAQ:VRDN) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, profitability, valuation and risk.

Valuation and Earnings

This table compares Viridian Therapeutics and Evaxion Biotech A/S's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridian TherapeuticsN/AN/AN/AN/AN/A
Evaxion Biotech A/SN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for Viridian Therapeutics and Evaxion Biotech A/S, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viridian Therapeutics00203.00
Evaxion Biotech A/S00203.00

Viridian Therapeutics currently has a consensus target price of $34.00, indicating a potential upside of 130.35%. Evaxion Biotech A/S has a consensus target price of $18.00, indicating a potential upside of 176.07%. Given Evaxion Biotech A/S's higher probable upside, analysts plainly believe Evaxion Biotech A/S is more favorable than Viridian Therapeutics.

Profitability

This table compares Viridian Therapeutics and Evaxion Biotech A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viridian TherapeuticsN/AN/AN/A
Evaxion Biotech A/SN/AN/AN/A

Summary

Evaxion Biotech A/S beats Viridian Therapeutics on 1 of the 1 factors compared between the two stocks.


Viridian Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
LBPH
Longboard Pharmaceuticals
1.9$11.63+7.0%$196.75 millionN/A0.00Analyst Report
Quiet Period Expiration
Gap Down
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$10.10+3.4%$193.10 millionN/A0.00Increase in Short Interest
Gap Up
GANX
Gain Therapeutics
1.7$14.50+2.8%$164.30 millionN/A0.00Analyst Revision
News Coverage
Gap Down
Annovis Bio logo
ANVS
Annovis Bio
0.0$21.55+0.1%$149.71 millionN/A0.00
VINC
Vincerx Pharma
1.0$17.60+4.0%$144.41 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$6.52+18.4%$125.18 millionN/A0.00Gap Up
LGVN
Longeveron
0.3$6.52+9.5%$123.60 millionN/A0.00News Coverage
Gap Down
UPC
Universe Pharmaceuticals
0.0$3.87+6.5%$84.17 millionN/A0.00Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.24+3.4%$52.67 millionN/A0.00Gap Down
VIRI
Virios Therapeutics
1.3$5.58+1.1%$46.48 millionN/A0.00News Coverage
Gap Down
VIRX
Viracta Therapeutics
1.7$8.00+0.4%$41.39 millionN/A0.00
VYNT
Vyant Bio
0.0$3.65+0.3%$40.18 millionN/A0.00News Coverage
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.20+6.3%$37.69 millionN/A0.00News Coverage
VLON
Vallon Pharmaceuticals
0.3$4.55+2.0%$30.99 millionN/A0.00News Coverage
VRPX
Virpax Pharmaceuticals
0.3$4.36+3.2%$23.39 millionN/A0.00Gap Up
CMMB
Chemomab Therapeutics
0.0$27.26+23.2%$12.65 millionN/A0.00Gap Down
BCTX
BriaCell Therapeutics
0.0$3.26+0.6%$2.52 millionN/A0.00News Coverage
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.57+4.7%$0.00N/A0.00Gap Up
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08+0.0%$0.00N/A0.00High Trading Volume
Gap Up
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06+0.0%$0.00N/A0.00News Coverage
BMEA
Biomea Fusion
0.0N/AN/A$0.00N/A0.00High Trading Volume
RXRX
Recursion Pharmaceuticals
0.0N/AN/A$0.00N/A0.00High Trading Volume
RPHM
Reneo Pharmaceuticals
0.3$13.00+2.4%$0.00N/A0.00Insider Buying
News Coverage
SCPS
Scopus BioPharma
1.4$7.54+3.3%$0.00N/A0.00Increase in Short Interest
News Coverage
Gap Down
VECT
VectivBio
0.0$16.12+1.8%$0.00N/A0.00News Coverage
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.